AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 55,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
107% more first-time investments, than exits
New positions opened: 257 | Existing positions closed: 124
47% more funds holding in top 10
Funds holding in top 10: 165 [Q4 2024] → 242 (+77) [Q1 2025]
15% more call options, than puts
Call options by funds: $3.94B | Put options by funds: $3.43B
13% more capital invested
Capital invested by funds: $232B [Q4 2024] → $263B (+$31.2B) [Q1 2025]
1% more funds holding
Funds holding: 3,673 [Q4 2024] → 3,715 (+42) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 1,460 | Existing positions reduced: 1,577
1.09% less ownership
Funds ownership: 72.04% [Q4 2024] → 70.95% (-1.09%) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$194
2%
upside
Avg. target
$215
13%
upside
High target
$250
31%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Citigroup Geoff Meacham | 7%upside $205 | Neutral Downgraded | 14 May 2025 |
Guggenheim Vamil Divan | 13%upside $216 | Buy Maintained | 29 Apr 2025 |
Raymond James Gary Nachman | 19%upside $227 | Outperform Maintained | 28 Apr 2025 |
Evercore ISI Group Gavin Clark-Gartner | 7%upside $205 | Outperform Maintained | 28 Apr 2025 |
Morgan Stanley Terence Flynn | 31%upside $250 | Overweight Maintained | 28 Apr 2025 |
Financial journalist opinion
Based on 52 articles about ABBV published over the past 30 days
Neutral
CNBC Television
1 day ago
Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie
The Investment Committee debate the latest Calls of the Day.
Neutral
GlobeNewsWire
2 days ago
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market.
Neutral
PRNewsWire
3 days ago
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition, but patients can often go undiagnosed.1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as cirrhosis or liver cancer1 The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity, and supports public health goals for disease elimination NORTH CHICAGO, Ill. , June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy.
Positive
Zacks Investment Research
3 days ago
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Neutral
Seeking Alpha
4 days ago
AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
AbbVie Inc. (NYSE:ABBV ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A. Michael - CEO & Director Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott T.
Positive
Zacks Investment Research
4 days ago
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Positive
The Motley Fool
6 days ago
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
How would you like to get paid every quarter (and sometimes every month) to own a stock? That's exactly what happens when you invest in dividend stocks.
Positive
Market Watch
1 week ago
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Positive
Zacks Investment Research
1 week ago
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
Negative
Zacks Investment Research
1 week ago
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.
Charts implemented using Lightweight Charts™